A protein called PIEZO1, which helps cells in blood vessels detect mechanical forces, plays a key role in driving pulmonary fibrosis (PF), a new study indicates. Findings suggest that blocking the activity of PIEZO1 and the signaling pathway it controls may be a useful strategy for developing new…
News
The U.S. Food and Drug Administration (FDA) has approved a generic version of Ofev (nintedanib) for easing lung scarring in people with idiopathic pulmonary fibrosis (IPF). The new generic nintedanib oral capsules, available in 100 mg and 150 mg dosages, will be marketed by Cipla. In a…
A compound called orcinol glucoside (OG) can reduce lung inflammation and scarring in mouse and cell models of idiopathic pulmonary fibrosis (IPF), according to the findings of a new study, which suggests that OG could prove to be a treatment for the lung condition. The lab study results indicate…
Treatment with Tyvaso (treprostinil) outperformed a placebo at preserving lung function and preventing clinical worsening — meaning, it led to gains beyond temporary symptom changes — among people with idiopathic pulmonary fibrosis (IPF) in the now-completed global TETON-2 clinical trial. United Therapeutics, Tyvaso’s developer and the study’s sponsor,…
Trevi Therapeutics plans to launch two pivotal Phase 3 clinical trials to continue testing Haduvio (nalbuphine extended-release) as a treatment for people with idiopathic pulmonary fibrosis (IPF) who have chronic cough. A pivotal study is one in which results, if positive, are used to support applications for a…
Following the lifting of a regulatory hold late last year, a U.S. clinical trial testing LTI-03, an inhaled therapy for people with idiopathic pulmonary fibrosis (IPF), is now fully underway. Treatment developer Rein Therapeutics announced that dosing has started in the Phase 2 clinical trial, which aims to assess the…
Regulatory authorities in both the U.S. and the European Union have granted orphan drug status to deupirfenidone (LYT-100), an oral therapy Puretech Health is developing to treat idiopathic pulmonary fibrosis (IPF). This designation aims to provide extra economic incentives to companies that invest in developing medications for rare…
Mutations in the ACVRL1 gene may play a role in the development of idiopathic pulmonary fibrosis (IPF), and targeting the gene — until now, little noted, according to researchers — could potentially lead to new treatments for the respiratory disease, a study suggests. Additionally, according to the scientists, the study…
Treatment with Esbriet (pirfenidone) reduces the risk of irregular heartbeat by nearly 90% in adults with idiopathic pulmonary fibrosis (IPF), according to a new study. Use of the approved IPF drug also eased the worsening of atrial arrhythmias — irregular heartbeats originating in the upper chambers of the heart —…
New Phase 2a clinical trial data suggest that treatment with GRI-0621, an experimental oral therapy from GRI Bio, altered the activity of genes linked to inflammation and lung scarring (fibrosis) in adults with idiopathic pulmonary fibrosis (IPF). The therapy was also associated with increased activity of genes involved…
